Neuland Laboratories Limited has informed the Exchange regarding a press release dated April 01, 2026, titled "Press Release".
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Neuland Laboratories has appointed Saharsh Davuluri as its new Chief Executive Officer and Managing Director, effective immediately. He succeeds Sucheth Davuluri, who will now serve as Executive Vice Chairman. Saharsh has been with the company for over 18 years and previously led Neuland's transformation into an NCE-focused drug substance CDMO. The company highlighted that its contract services revenues have tripled over the last 3 years, and it plans to aggressively expand commercial peptide capacity and double process development capabilities. Neuland operates three US FDA-inspected manufacturing facilities with 1,218 KL of installed capacity and over 20 commercial contracts.
This is a planned leadership transition with continuity, as the new CEO is a long-tenured insider. The move signals sharper focus on CDMO expansion, particularly in peptides and commercial NCE contracts, which could support future growth and may be viewed positively by investors.